エクシキュア
Exicure, Inc.
Exicure, Inc. does not have significant operations. Previously, it focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. The company has a co-development agreement with Adbiotech Co., Ltd. to explore combination therapies based on Burixafor (GPC-100) across multiple therapeutic areas. Exicure, Inc. was founded in 2011 and is headquartered in Redwood City, California.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q2 | -0.18 | $0 | -$887,000 |
| 2026 Q1 | -0.29 | $0 | -$1M |
| 2025 Q4 | -0.45 | $0 | -$934,000 |
| 2025 Q3 | -0.39 | $0 | -$3M |
| 2025 Q2 | -0.41 | $0 | -$3M |
| 2025 Q1 | 0.49 | $0 | -$2M |
| 2024 Q4 |
| -1.19 |
| $0 |
| -$845,000 |
| 2024 Q3 | -0.15 | $0 | -$449,000 |